Anaplastic Lymphoma Kinase clinical trials

Explore recruiting anaplastic lymphoma kinase clinical trials.

Recruiting anaplastic lymphoma kinase studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anaplastic Lymphoma Kinase trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Poland, Spain, Portugal, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine

Austria, Germany, Netherlands, Belgium, Denmark, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Poland, France, Spain, Czechia, Belgium, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Belgium, Netherlands, France, Spain, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Anaplastic Lymphoma Kinase trials by city

Anaplastic Lymphoma Kinase in Toronto Anaplastic Lymphoma Kinase in Vancouver Anaplastic Lymphoma Kinase in Montreal Anaplastic Lymphoma Kinase in Calgary Anaplastic Lymphoma Kinase in Edmonton Anaplastic Lymphoma Kinase in Ottawa Anaplastic Lymphoma Kinase in Winnipeg Anaplastic Lymphoma Kinase in Quebec City Anaplastic Lymphoma Kinase in Hamilton Anaplastic Lymphoma Kinase in Kitchener Anaplastic Lymphoma Kinase in London Anaplastic Lymphoma Kinase in Halifax Anaplastic Lymphoma Kinase in New York Anaplastic Lymphoma Kinase in Los Angeles Anaplastic Lymphoma Kinase in Chicago Anaplastic Lymphoma Kinase in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease